QTTB Financials Q32 Bio Inc.
9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $54M | $30M | 0.0% | 31.5% | 70.9% | 48.2% | -$34M | — | $48M |
| 2024 | $0 | -$48M | — | — | -840.5% | -51.7% | -$68M | — | $78M |
| 2023 | -$7M | -$54M | 0.0% | 725.5% | 29.4% | -114.1% | -$19M | — | $26M |
| 2022 | — | -$5M | — | — | 3.8% | -2.2% | -$115M | — | $34M |
| 2021 | — | -$96M | — | — | -56.4% | -45.2% | -$112M | — | $108M |
| 2020 | — | -$129M | — | — | -65.7% | -48.8% | -$98M | — | $217M |
| 2019 | — | -$104M | — | — | -40.2% | -33.5% | -$113M | — | $54M |
| 2018 | $4M | -$56M | 0.0% | -1626.7% | -28.3% | -21.5% | -$68M | — | $38M |
| 2017 | — | -$30M | — | — | 76.0% | -21.8% | $5M | — | $52M |
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$9M | — | — | -8.4% | -7.7% | — | — | $106M |
| Mar '26 | — | -$8M | — | — | -16.4% | -11.9% | — | — | $51M |
| Dec '25 | — | $58M | — | — | 137.4% | 93.5% | -$6M | — | $48M |
| Sep '25 | — | -$7M | — | — | 40.1% | -12.8% | -$4M | — | $49M |
| Jun '25 | — | -$9M | — | — | 77.6% | -14.4% | — | — | $55M |
| Mar '25 | — | -$11M | — | — | 274.8% | -14.0% | — | — | $65M |
| Dec '24 | $0 | -$14M | — | — | -250.0% | -15.4% | -$11M | — | $78M |
| Sep '24 | $0 | -$18M | — | — | -96.2% | -16.8% | -$20M | — | $89M |
| Jun '24 | $0 | -$17M | — | — | -50.7% | -13.7% | -$22M | — | $98M |
| Mar '24 | $0 | $1M | — | — | 2.1% | 0.7% | -$15M | — | $116M |
| Dec '23 | -$15M | -$27M | 0.0% | 176.0% | 14.8% | -57.5% | -$11M | — | $26M |
| Sep '23 | $2M | -$14M | 0.0% | -419.5% | 9.0% | -10.0% | $16M | — | $36M |
| Jun '23 | $3M | -$6M | 0.0% | -227.0% | 4.1% | -3.4% | -$11M | — | $20M |
| Mar '23 | $3M | -$7M | 0.0% | -250.2% | 5.0% | -3.5% | -$13M | — | $31M |
| Dec '22 | — | -$34M | — | — | 26.2% | -15.0% | -$27M | — | $34M |
| Sep '22 | — | -$34M | — | — | -16.1% | -12.8% | -$25M | — | $43M |
| Jun '22 | — | -$29M | — | — | -12.1% | -10.2% | -$31M | — | $176M |
| Mar '22 | — | $92M | — | — | 34.6% | 29.6% | -$32M | — | $248M |
| Dec '21 | — | -$34M | — | — | -19.8% | -15.9% | -$31M | — | $108M |
| Sep '21 | — | -$31M | — | — | -15.4% | -13.3% | -$26M | — | $96M |
Valuation over time
How the market has priced QTTB against its own fundamentals since 2024-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has risen from 3.3× (Dec '25) to 12.8× (Sep '26).
- The price-to-sales ratio has risen from 1.8× (Dec '25) to 7.1× (Sep '26).
Frequently asked questions
Is QTTB growing its revenue and profit?
See the revenue and net-income charts above for Q32 Bio Inc.'s multi-year trend.
How much debt does QTTB have?
As of FY2025, Q32 Bio Inc. reported — of total debt against $48M of cash.
What is QTTB's profit margin?
In FY2025, gross margin was —, operating margin 31.5%, and net margin 55.5%.
What is QTTB's P/E ratio?
As of Sep '26, Q32 Bio Inc. traded at a price-to-earnings ratio of about 12.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.